These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34325112)

  • 1. Analysis of Google Trends to monitor new psychoactive substance. Is there an added value?
    Batistic FK; Rhumorbarbe D; Lefrancois E; Tettey J; Raithelhuber M; Rossy Q; Morelato M
    Forensic Sci Int; 2021 Jul; 326():110918. PubMed ID: 34325112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Psychoactive Substances: A Potential Threat to Developing Countries.
    Hasan M; Sarker SA
    Addict Health; 2023 Apr; 15(2):136-143. PubMed ID: 37560390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise.
    Catalani V; Corkery JM; Guirguis A; Napoletano F; Arillotta D; Zangani C; Vento A; Schifano F
    Eur Neuropsychopharmacol; 2021 Aug; 49():69-92. PubMed ID: 33857740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances.
    Guillou C; Reniero F; Lobo Vicente J; Holland M; Kolar K; Chassaigne H; Tirendi S; Schepers H
    Curr Pharm Biotechnol; 2018; 19(2):91-98. PubMed ID: 29792142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Air monitoring for illegal drugs including new psychoactive substances: A review of trends, techniques and thermal degradation products.
    Gent L; Paul R
    Drug Test Anal; 2021 Jun; 13(6):1078-1094. PubMed ID: 33870654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Psychonauts' World of Cognitive Enhancers.
    Napoletano F; Schifano F; Corkery JM; Guirguis A; Arillotta D; Zangani C; Vento A
    Front Psychiatry; 2020; 11():546796. PubMed ID: 33024436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.
    Miliano C; Serpelloni G; Rimondo C; Mereu M; Marti M; De Luca MA
    Front Neurosci; 2016; 10():153. PubMed ID: 27147945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach.
    Catalani V; Arillotta D; Corkery JM; Guirguis A; Vento A; Schifano F
    Front Psychiatry; 2020; 11():632405. PubMed ID: 33633599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMCDDA framework and practical guidance for naming synthetic cannabinoids.
    Pulver B; Fischmann S; Gallegos A; Christie R
    Drug Test Anal; 2023 Mar; 15(3):255-276. PubMed ID: 36346325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day.
    Andrews R; Jorge R; Christie R; Gallegos A
    Drug Test Anal; 2023 Apr; 15(4):378-387. PubMed ID: 36507715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interest in eight new psychoactive substances before and after scheduling.
    Ledberg A
    Drug Alcohol Depend; 2015 Jul; 152():73-8. PubMed ID: 25981311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.